Literature DB >> 20606759

Comparison among plasma-derived clotting factor VIII by using monodimensional gel electrophoresis and mass spectrometry.

Anna Maria Timperio1, Federica Gevi, Giuliano Grazzini, Stefania Vaglio, Lello Zolla.   

Abstract

BACKGROUND: Deficiency or dysfunction of coagulation factor VIII (FVIII) is the underlying cause of haemophilia A. Haemophilic patients are at present treated with plasma-derived FVIII (pdFVIII) or recombinant FVIII (rFVIII) in order to correct their clotting deficiency. pdFVIII concentrates are exclusively produced from human plasma upon pooling from multiple donors. It is not know whether the presence of excess of other plasma proteins, in addition to von Willebrand factor, could stimulate untoward immune responses in the recipient. Thus, information regarding the presence of contaminants in commercial products is of concern.
MATERIALS AND METHODS: Two commercially available pdFVIII concentrates were characterized through SDS-PAGE and mass spectrometry Emoclot and Beriate.
RESULTS: The components of two pdFVIII products considered in this study were well identified by mass spectrometry analysis, in both cases we found abundant components coming from blood plasma, and some other contaminants. Only in Beriate we also found truncated form of pdFVIII.
CONCLUSION: The two pdFVIII examined showed the presence of vWF, Fibrinogen in excess, and other substances that could be considered as contaminants or impurities.

Entities:  

Keywords:  SDS-PAGE; contaminants; haemophilia A; mass spectrometry; plasma derived FVIII

Mesh:

Substances:

Year:  2010        PMID: 20606759      PMCID: PMC2897196          DOI: 10.2450/2010.016S

Source DB:  PubMed          Journal:  Blood Transfus        ISSN: 1723-2007            Impact factor:   3.443


  35 in total

Review 1.  Biochemistry and physiology of blood coagulation.

Authors:  K G Mann
Journal:  Thromb Haemost       Date:  1999-08       Impact factor: 5.249

2.  Proteomic characterization of inter-alpha inhibitor proteins from human plasma.

Authors:  Djuro Josic; Mari Kino Brown; Feilei Huang; Yow-Pin Lim; Marijana Rucevic; James G Clifton; Douglas C Hixson
Journal:  Proteomics       Date:  2006-05       Impact factor: 3.984

3.  Characterisation of a novel high-purity, double virus inactivated von Willebrand Factor and Factor VIII concentrate (Wilate).

Authors:  M Stadler; G Gruber; C Kannicht; L Biesert; K U Radomski; H Suhartono; K Pock; A Neisser-Svae; J Weinberger; J Römisch; T-E Svae
Journal:  Biologicals       Date:  2006-02-23       Impact factor: 1.856

4.  The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von willebrand factor.

Authors:  E L Saenko; D Scandella
Journal:  J Biol Chem       Date:  1997-07-18       Impact factor: 5.157

Review 5.  Galectins. Structure and function of a large family of animal lectins.

Authors:  S H Barondes; D N Cooper; M A Gitt; H Leffler
Journal:  J Biol Chem       Date:  1994-08-19       Impact factor: 5.157

6.  The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups.

Authors:  R Prescott; H Nakai; E L Saenko; I Scharrer; I M Nilsson; J E Humphries; D Hurst; G Bray; D Scandella
Journal:  Blood       Date:  1997-05-15       Impact factor: 22.113

Review 7.  Degradation products of factor VIII which can lead to increased immunogenicity.

Authors:  D Josić; A Buchacher; C Kannicht; Y P Lim; K Löster; K Pock; S Robinson; H Schwinn; M Stadler
Journal:  Vox Sang       Date:  1999       Impact factor: 2.144

Review 8.  The need for previously untreated patient population studies in understanding the development of factor VIII inhibitors.

Authors:  E D Gomperts
Journal:  Haemophilia       Date:  2006-11       Impact factor: 4.287

Review 9.  Do galectins play a role in venous thrombosis? a review.

Authors:  Jose A Diaz; Eduardo Ramacciotti; Thomas W Wakefield
Journal:  Thromb Res       Date:  2009-12-02       Impact factor: 3.944

10.  Galectin 3-binding protein is a potential contaminant of recombinantly produced factor IX.

Authors:  M Blostein; J Cuerquis; J Galipeau
Journal:  Haemophilia       Date:  2007-11       Impact factor: 4.287

View more
  1 in total

1.  Plasma Polyethylene Glycol (PEG) Levels Reach Steady State Following Repeated Treatment with N8-GP (Turoctocog Alfa Pegol; Esperoct®).

Authors:  Inga Bjørnsdottir; Birgitte Støvring; Tue Søeborg; Helene Jacobsen; Ola Sternebring
Journal:  Drugs R D       Date:  2020-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.